ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TRLS Trellus Health Plc

1.65
0.00 (0.00%)
23 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Trellus Health Plc LSE:TRLS London Ordinary Share GB00BNNFM402 ORD GBP0.0006
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.65 1.50 1.80 1.65 1.65 1.65 50,310 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices Of Medical Doctors 19k -6.34M -0.0392 -0.42 2.66M
Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 1.65p. Over the last year, Trellus Health shares have traded in a share price range of 1.65p to 9.20p.

Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £2.66 million. Trellus Health has a price to earnings ratio (PE ratio) of -0.42.

Trellus Health Share Discussion Threads

Showing 251 to 274 of 325 messages
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
DateSubjectAuthorDiscuss
24/2/2023
15:00
Look. IMVHO, this is not a business to public thing. As a result there are vested interests in maintaining the status quo with a wide variety of vested interests from billing for direct in-person treatment to pension funds and pharma and medical tools. This is a grower, not a show-er. No sense in drawing attention to it. It looks happy enough in my ISA 😎
casholaa
24/2/2023
14:47
Idomeneo...I agree that the CEO is excellent.

Certainly the share price performance appears to be reflecting disappointment, and not reporting as guided is clearly not helping matters. And lets face it, whilst the recent updates have been encouraging, none of them have been game changing, but they should nonetheless contribute positively this year.

The increasing interest from pharmaceutical companies and the progression to late-stage discussions (with at least two), might change the dynamics if they can successfully conclude something material.

Perhaps those discussions are taking longer, and they had hoped to include them as part of the detailed trading update, which in turn would imply they might be close to concluding?

I also have my eye on larger entities in the healthcare space where partnering with Trellus in addressing chronic conditions (initially IBD & IBS), could make a good fit strategically (expanding to address other chronic conditions, and/or some already covered by those entities), especially given that Trellus Health is the first and only digital health company to offer a 'scientifically validated', personalised resilience-based self-management training program for people living with chronic conditions which has been proven to reduce unplanned hospitalizations by 94%.

After the disappointingly slow progress to date though, and the market in a state of being very unforgiving, updates of only incremental progress will hardly be well received given the early stage Trellus is at.

wan
24/2/2023
13:03
I am just sitting tight. In my mind what is being sold is time and money for health professionals and estalishments. Best kept under the radar for now 😃
casholaa
24/2/2023
12:34
"The Company expects to provide a more detailed trading update by early February 2023." It's late February and so far nothing.
CEO was saying on the 3rd October call that she had been "strategically insulated" but there would now be a lot more news flow and evidence of the financial benefits. Since October the best news has been the agreement with New York State-based health
insurer to offer the Trellus IBD program to up to 50 of its members over a
12-month period. So they just need another 7020 more to break even.
As far as I can tell nothing is happening with the b2c with the app which is surely where some money should be coming in. The downloads are negligible, so I don't see what will change to make this increase. In theory they the app is being pushed by the relevant IBD groups, but for whatever reason this is not translating into downloads (and therefore payments). If you are not being "sold" the Trellus System why would you choose it of your own volition?
I'm really scratching my head with this one. The CEO appears competent and dynamic but it would appear that the company will need all the funding it has and more to get this off the ground. After the call I was expecting that before now there would have been at least one announcement in the vein of "we have signed up XYZ Insurance Scheme which covers 3 million people and they will offer it to their 9000 IBD clients" All we have so far is a trial, which doesn't sound like they have been able to sell what they do without the insurer checking it for themselves despite the clinical evidence.

At a launch price of 40p: "The Company expects to generate initial revenue in 2021 through demonstration projects with healthcare payers in the New York City metropolitan area". So what happened to that? Why isn't that generating revenue now? Agreements and understandings mean nothing without a clear indication of the likely imminent revenue.

Has anybody any evidence of better actual financial news? Wouldn't it have been better to have made an announcement explaining why they were delaying the promised early Feb update?

idomeneo
21/2/2023
15:56
This is not the first I've heard from unfortunate people like LondonMarket about a the shambolic and disjointed approach the health service has to treating IBS and IBD. I doubt it's much better in the States so I reckon TRLS's offering will go down a storm over there and welcomed as a gift from the gods by clinicians who are probably frustrated at their inability to treat to their own satisfaction. The NHS is a different matter because it's turgid bureaucracy is a real block to innovation.
mikemine1
19/2/2023
22:04
As someone with IBD (Crohn's) I would love for the NHS IBD management teams to start using platforms such as the one Trellus are developing.

Currently, it's a mix of emails, phone calls and letters for long-term IBD management (monitoring, testing & treatment) which aside from being costly, timely and probably more expensive it's also a massive security risk. More than once I've received messages or blood test forms meant for another patient under the team. It's an antiquated way of managing patients which could be easily fixed and improved with the Trellus system from what I understand

londonmarket
17/2/2023
07:41
Further news today regarding the inclusion of IBS as well as IBD, and also the expansion of one of their existing agreements with the Mount Sinai Health System. In short, the Trellus Method is now available to a much larger target patient population by addressing resilience in IBS as well as IBD.

In my view, the increase in the generation of real-world evidence of the health and economic outcomes from expanding into both IBD and IBS, will not only support B2B2C engagement, but potentially provide further support to expand into other chronic conditions. Trellus has already stated that they believe its methods have utility across a number of other chronic conditions.

Recall also that The Company expects to provide a more detailed trading update this month.

wan
13/2/2023
09:34
I meant to post this article at the weekend, which aligns quite well with the progress Trellus has recently made. This article implies there is much more to come (and it looks like there could be more to come from Trellus) -

Using a Digital Doorway for Behavioral Health Support in 2023

Behavioral health will continue to take center stage in 2023. It is critical that industry stakeholders collaborate to identify critical mental health needs and leverage available technology to produce meaningful change.
By PETER STRIMAITIS

Feb 10, 2023

As the unpredictability of mental health services persists, here are three trends to watch for in 2023:

Digital expansion

For the past two years, the behavioral health industry has evolved tremendously to adapt to current consumer demands. Companies shifted all counseling to online sessions, providing more convenient care and improving care coordination. Virtual appointments are now easier for people to schedule and attend, remote monitoring improves chronic condition management for numerous conditions, telemedicine drastically decreases costs, and a familiar environment is proven to have a positive effect on patient outcomes.

Organizations also expanded the breadth of their services, branching out into less conventional territories. Increased accessibility allows organizations to address other issues such as population health and health equity. Moving forward, care models will continue to deviate from traditional models to include more digital options and provide a more consumer-friendly experience for behavioral health care.

Moreover, the current trend of employee benefit expansion will carry on. More organizations will develop employee assistance programs (EAPs) that encompass an integrated suite of offerings instead of the historically accepted few. Companies will begin to add more mental health-related services to their existing programs. These extensions should include adding health screenings, health coaching, teletherapy, and other digital tools that comprise a “digital doorway.”

Full article -

wan
13/2/2023
07:55
With today's news, that now completes 3 of contracts highlighted in Trellus' Half-year Report -

Significant progress with advancing B2B2C model
I am very pleased to report that, despite the longer lead times in the B2B2C contracting process as previously reported in December 2021, we have made significant progress in advancing a number of conversations with payers , such as regional and national health plans, employers, health systems, GI provider networks, and pharmaceutical companies. Whilst we have launched our D2C model, we remain focused on our B2B2C offering which provides better quality patient outcomes at lower costs to health plans and employers.

We are in productive conversations with two health plans, having entered late-stage discussions with one and starting the due diligence process with another; we are in the final contracting phase for a New York Medicaid plan and we have two further contracts, one with a large NY State employer and the other with a NY State Provider to support members of a large NY labor union, which we expect to be signed soon.

We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform.

Expansion into Irritable Bowel Syndrome (IBS) for comprehensive GI solution



Hopefully we will see continued execution in IBS expansion and the pharma discussions/contracts that were also referred to, not to mention "The Company expects to provide a more detailed trading update by early February 2023."

wan
02/2/2023
08:57
A couple of excerpts from the Half-year Report -

"Following Our initial focus was on IBD, a lifelong chronic disease plagued by mismanagement, improper treatment, high costs and rates of anxiety, depression and emergency healthcare utilization. However last year , we initiated research into versioning Trellus Resilience Training into IBS, another chronic GI condition that has significant similarities with IBD from a symptom burden and emotional perspective. IBS however has a much higher population prevalence than IBD, impacting c. 10% of the US population (c. 30m patients for IBS compared to c. 3m for IBD). Whilst the annual healthcare spend on IBS is higher at c. $61 bn (IBD c $25 bn), this is significantly lower than IBD on a "per patient" basis.

Originally, we had expected to launch the Trellus Method for IBS in H1 2023, however using existing resources we have accelerated the launch of our IBS application which is now expected at the start of Q1 2023, when we will be offering patients a comprehensive GI solution covering both IBD and IBS. We also believe our solution can be used across many other chronic conditions to deliver meaningfully improved healthcare outcomes as well as reducing expensive, unplanned care, such as emergency department visits and hospitalisations."


And from the 20th Dec 2022 update -

"The Company expects to provide a more detailed trading update by early February 2023."
(END)

I note that Trellus has now widened their offering to include IBS -

Digestive Health Support, Reimagined
Trellus Health supports and empowers people living with Crohn's disease, ulcerative colitis, and IBS. Using our clinically proven program, Trellus Health helps you manage your health and live a fuller life.


Trellus Health for Individuals with Irritable Bowel Syndrome -

wan
19/1/2023
08:53
The market is still unimpressed with Trellus, despite some positive news flow and change etc, but the market obviously wants more than a just a positive backdrop in terms of prospects.

To repeat: Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS.

I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. But the dynamics appear to be on the cusp of change with regard to pharma developments related to IBD.

From the Trellus Health Half-year Report -

"We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform."

Pharmaceutical competition looks set to increase, which may increase the attention, and intensify the ongoing discussions with Trellus -

January 17, 2023

Digesting 2022 and looking forward to 2023 in IBD therapeutics

The past year has seen quite a few new developments in inflammatory bowel disease therapy.

Other important developments to anticipate in 2023 include the introduction of as many as eight adalimumab biosimilars to the U.S. market, which almost certainly will drive the price of adalimumab down, and the potential approvals of subcutaneous Entyvio (vedolizumab, Takeda) and Inflectra (infliximab-dyyb, Celltrion) for the treatment of IBD.

These therapeutics have already been approved in multiple other regions including Europe. It will be interesting to see what effect the availability of the adalimumab biosimilars and subcutaneous vedolizumab and infliximab-dyyb will have on treatment algorithms, especially if the cost differences are significant.

I suspect it will take time for us to “digest” all these new developments, and the publication of real-world experiences with these new agents will help shape our clinical practice. Here’s looking to 2023!

Full article -

Food for thought: Dr. Dubinsky is co-founder and equity owner in a MiTest Health, which received a licensing fee from Takeda for CDPATH. Dr. Dubinsky has received compensation from both Takeda Pharmaceutical and Prometheus Laboratories as a consultant. In addition to Takeda, Dr. Dubinsky also serves as a paid consultant for other pharmaceutical companies that develop and/or manufacture treatments for inflammatory bowel disease (IBD). Dr. Dubinsky is co-founder and equity owner of two start-up companies involved in IBD healthcare, Trellus Health and GoDoRun.

wan
04/1/2023
09:28
A worthy and thought-provoking read -

10 Key Medtech Themes for 2023
We expect 2023 to be a pivotal year for the industry, as the accelerated acceptance of virtual care and demographic trends, such as an aging population, increasing chronic illnesses and healthcare worker shortages, sustain demand for medtech-enabled solutions.
By VINITA KAILASANATH AND SORA PARK

Jan 3, 2023

wan
20/12/2022
07:36
Todays RNS confirms the cash position at year end is slightly better than expected and reflecting the Company's close control of cash, which is close to my previous estimate -

"Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only."

Further updates to follow -

The Company expects to provide a more detailed trading update by early February 2023.

The Company expects to provide further commentary on its business development opportunities when it issues its further update in early 2023.

Recall also the following from the Half-ear Results -

Originally, we had expected to launch the Trellus Method for IBS in H1 2023, however using existing resources we have accelerated the launch of our IBS application which is now expected at the start of Q1 2023, when we will be offering patients a comprehensive GI solution covering both IBD and IBS. We also believe our solution can be used across many other chronic conditions to deliver meaningfully improved healthcare outcomes as well as reducing expensive, unplanned care, such as emergency department visits and hospitalisations.
(END)

I my view, with the shares trading at 11p, the upside potential is meanly priced in!

wan
07/12/2022
07:46
Above link sorted
wan
07/12/2022
07:44
Staying with the pharma angle -


1 day ago

Day 1 at the #AIBD conference, and there was no shortage of fantastic speakers!

Our CEO and cofounder Dr. Marla Dubinsky
presented at the Pediatric Track Breakout session, leading a discussion called “Brave New World: Navigating and Positioning the Growing Armentarium of Biologics for Pediatric Patients”.

Within her presentation, she discussed the fundamental principles in the approach to positioning IBD therapies and the importance of personalization, what drives the need for different therapies, switching from an empiric approach to a more biologic approach, and the relative efficacy of biologics for induction and maintenance therapies for Crohn’s disease and ulcerative colitis.


For more on the above from the AIBD conference -

Marla Dubinsky, MD, on Brave New World: Positioning Biologics for Pediatric Patients With IBD

Dr Dubinsky reviews her keynote presentation on the use of newer biologics with pediatric patients with inflammatory bowel diseases.

wan
07/12/2022
07:39
Very well deserved!
Trellus CEO has been awarded the Sherman Prize, the video contained within the link is worth watching too -

14hrs ago
Congratulations to our CEO and cofounder, Dr. Marla Dubinsky on receiving the Sherman Prize this morning at the #AIBD Conference. Your passion for improving patient lives and innovative approaches to #IBD medicine are truly admirable. We are truly fortunate to have such an inspirational leader at our organization, and congratulations again for this tremendous honor!



2022 PIONEERS
Recipients stories -
Going above and beyond in the fight to overcome
Crohn's disease and ulcerative colitis.

wan
06/12/2022
09:43
Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only.

I note that Trellus has updated/revamped their website -


Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS.

I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. A reminder -

"We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform."

wan
11/11/2022
07:29
Medtech execs ‘rethink’ long-term strategies as care settings shift: Accenture report
Published Nov. 10, 2022

Dive Brief:
More than 75% of surveyed medtech executives expect expanding care settings and delivery models to “significantly re-orient their company’s long-term strategy.”

Dive Insight:
The COVID-19 pandemic accelerated shifts that were already underway in the industry, notably moves from in-person to virtual interactions and from hospital to ambulatory care centers. According to Accenture’s report, which is based on the survey and interviews with 30 digital health senior executives and C-suite leaders, the shift in where care happens is only just beginning.

“We estimate that 80% to 90% of chronic and behavioral care can shift to virtual. It means that providers are able to work to the full extent of their medical training, rather than burning time on more menial tasks,” an unidentified executive at AdvaMed’s Digital Health Center of Excellence said in the report.

The surveyed and interviewed executives expect to transform their businesses in response to the shifts in how care is delivered. While traditional products still account for most sales, the executives see the expansion of care to new settings as part of their growth strategies. Accenture cited the use of diagnostic tests at physician’s offices or at home, rather than at large hospital labs, as an example of the changes.

Full article -

The above sits well with the recent news from Trellus -

LONDON, U.K. AND NEW YORK, U.S. (19 October 2022): Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that the Trellus Resilience Training and Self-Management Solution for Inflammatory Bowel Disease (the "Trellus IBD program") is now available on GI OnDemand, gastroenterology's leading multidisciplinary virtual integrated care platform .

GI OnDEMAND, a joint venture between the American College of Gastroenterology ("ACG") and Gastro Girl, Inc., now offers the Trellus IBD program, to all GI OnDEMAND and ACG members nationwide to coordinate and deliver personalized behavioral, emotional and nutritional support for their IBD patients remotely via digital solutions, and access to an expert resilience team via telehealth . The Trellus IBD program will be the only resilience driven self-management training solution offered via this platform to over 16,000 gastrointestinal ("GI") professionals across the US for the benefit of the millions of patients they collectively serve.

wan
10/11/2022
19:53
One very attractive aspect of the business model, as far as I can see, is that, once a patient comes on to the programme, they stay for a very long time, possibly for life. This means that TRLS have only one sale to make, if you like, to acquire a very long term pipeline of revenue. It's cumulative and should not be a linear growth as more and more clinicians should join the band of referrers.

This could be very big but patience will be required.

All my own opinion of course.

mikemine1
25/10/2022
12:15
I have Crohn's Disease. I will be talking about Trellus to all clinicians I can. The NHS IBD Team who manage me are overwhelmed, one consultant -> 3 nurses for a massive urban area of a disease which is only increasing in prevalence.
londonmarket
21/10/2022
04:17
Think of markets, link-ups, contracts etc. all you like but, for me, the big number here is TRLS has said they only need 8,000 patients to break even. Now look at all the potential patients the fore mentioned access points open up to Trellus. Do you think that number will come out of those tie-ups? To me it's a no brainer that the 8.000 will be exceeded and that means profit. The only question for me is when?

Ramp over......................for now.

mikemine1
19/10/2022
07:32
With today's announcement the transition to meaningful revenue generation appears well underway, but there could be more to come if the late stage discussions with two large pharmaceutical companies result in partnerships/contracts.

With a market cap that's still only marginally higher than cash, there should still be plenty of upside for the rerating to continue.

wan
18/10/2022
10:23
The last presentation by the management is a mus to listen to. Major points:

The biggest group of gastroenterologists in the US will announce on 22/23 October that the first port of call for people with IBS or IBD is Trellus. There are over 32 million people in US with one of the conditions .Their new CEO is a most respected docotr in this field.They also said there will be many positive announcements going forward. Additionally they have reduced their burn rate considerably. I like many on this site am a holder from when they first floated and therefore am holding paper losses however have bought more shares at 9.5p and 13p. See the presentation through Investor meet site well worth it

robin_lemer
04/10/2022
20:48
Making loads
theblackbaron
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older

Your Recent History

Delayed Upgrade Clock